Senores Pharmaceuticals Limited has informed the Exchange regarding a Corrigendum to the Media Release submitted with the Outcome of the Board Meeting dated May14, 2026
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Senores Pharmaceuticals filed a corrigendum to its earlier media release for Q4 and FY26 results, correcting a typing error in Annexure B. The corrected release shows exceptional performance with FY26 total income at Rs. 664 Crs (up 62% YoY), EBITDA at Rs. 200 Crs (up 96%), and PAT at Rs. 122 Crs (up 108%). Q4 standalone showed Total Income of Rs. 190 Crs (+58%), EBITDA of Rs. 62 Crs (+144%), and PAT of Rs. 37 Crs (+105%). All segments grew strongly: Regulated Markets revenue up ~75% to Rs. 427 Crs, Branded Generics surged ~385% to Rs. 40 Crs, and Emerging Markets rose ~20% to Rs. 145 Crs. The company also expanded through acquisitions (Apnar Pharmaceuticals, Zoraya Pharmaceuticals) and entered a U.S. Federal market JV (Amerisyn). Operating cash flow improved to Rs. 75 Crs.
The company posted outstanding growth across all metrics with over 100% PAT growth, strong cash generation, and a robust ANDA pipeline of 51 approvals. No fundamental concerns from this corrigendum — it is merely a typographical correction with no bearing on the financial outcomes.